Endorsement statement for resource producer (RE002)

**Lung cancer and mesothelioma service guidance during the COVID-19 pandemic**

This service guidance accurately reflects recommendations in the [COVID-19 rapid guideline: delivery of systemic anticancer treatments](https://www.nice.org.uk/guidance/ng161).

**National Institute for Health and Care Excellence**

*Endorsed: 15th June 2020*

*Review due: 15th September 2020, or sooner if the NICE COVID-19 rapid guideline changes*